We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Hyperactive Cysteine Sites Identified by New Quantitative Reactivity Technique

By LabMedica International staff writers
Posted on 14 Dec 2010
A publication described a new method for determining active regions on enzymes and other proteins by using specific probes in a fashion that discriminated between high and low affinity amino acid sites.

Investigators at the Scripps Research Institute (La Jolla, CA, USA) initially used the new technology to study the reactivity of cysteine residues in enzymes. More...
Cysteine is one of the most reactive of the amino acids and is often critically involved in determining the three-dimensional shape of protein molecules.

Two types of cysteine-specific probes were used. One probe bound to cysteine with high affinity while the other was less avid. This meant that by strictly controlling the concentration of the probe, they could determine whether it was binding to a particularly active or inactive cysteine site.

The investigators reported in the November 17, 2010, online edition of the journal Nature that they tested the technique on proteins found within a human breast cancer-cell line. They were able to identify and locate more than 800 cysteine sites on 522 proteins. For more than 90% percent of these cysteine sites the low and high concentration probes showed correspondingly low and high levels of labeling, indicating that the cysteine residues had ordinary reactivity. The other 10% of cysteine sites demonstrated a constant level of labeling for both low and high concentration probes, indicating that they were hyperreactive.

"What we have needed is a more efficient method to find and quantitatively analyze reactive sites,” said senior author Dr. Benjamin F. Cravatt, professor of chemical biology and physiology at the Scripps Institute, "not just for one protein in a purified sample but for a large set of proteins in their natural setting, such as within a whole cell or tissue.”

"It lets us find functional sites on proteins more efficiently than before, and that is going to be helpful not only for characterizing unknown proteins, but also for finding new sites of importance on already-characterized proteins. This is a relatively precise and straightforward method for screening designed proteins for functional properties,” said Dr. Cravatt. "It could be very useful for creating new enzyme catalysts for basic research and industrial applications.”

Related Links:

Scripps Research Institute



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.